STAAR Surgical Co. 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended October 3, 1997, and the nine-month period ended on that date. STAAR Surgical Company is a Delaware corporation headquartered in Monrovia, California, specializing in ophthalmic products including foldable intraocular lenses (IOLs), implantable contact lenses (ICL), and glaucoma treatment devices. As of November 12, 1997, the company had 13,160,920 shares of common stock outstanding.
Key Financial Metrics
| Metric | Nine Months Ended Oct 3, 1997 | Nine Months Ended Sep 27, 1996 |
|---|---|---|
| Total Revenues | $33,963,477 | $30,655,147 |
| Gross Profit | $26,048,928 (76.7% margin) | $23,304,309 (76.0% margin) |
| Operating Income | $8,959,654 | $7,336,096 |
| Net Income | $5,766,614 | $5,018,120 |
| Diluted EPS | $0.41 | $0.36 |
| Cash from Operations | $5,525,164 | $6,559,366 |
| Cash and Equivalents (End of Period) | $3,669,387 | $6,586,524 |
| Total Debt (Current + Long-term) | $4,855,914 | $8,233,599 |
| Current Ratio | 3.7:1 | 2.1:1 (Jan 3, 1997) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 10.8% year-over-year. International sales rose 28.4%, driven by demand for foldable IOLs and new product commercialization (STAAR Glaucoma Wick and ICL). U.S. sales increased 4.0% due to higher unit volume, partially offset by a 2.5% price decrease.
- Profitability: Gross margin improved to 76.7% from 76.0% due to operating efficiencies and economies of scale. Net income increased 14.9% to $5.77 million.
- Expense Management: Marketing and selling expenses decreased as a percentage of revenue (27.7% vs. 29.1%) due to revenue growth absorbing fixed costs. R&D expenses decreased to 8.9% of revenue.
- Liquidity and Debt: Cash and cash equivalents decreased by $2.8 million primarily due to debt repayments. Total debt was significantly reduced following a renegotiation of the line of credit in June 1997, which reclassified $4.2 million of debt from short-term to long-term, improving the current ratio to 3.7:1.
- Working Capital: Net working capital increased to $21.2 million from $15.0 million at the start of the fiscal year. Inventories increased to support international product rollouts.
Outlook, Risks, and Unusual Items
- Product Approvals: The company received European "CE Mark" approval for its Toric IOL, ICL, Glaucoma Wick, and StaarVisc. Phase I clinical trials for the ICL were completed, with FDA approval to begin Phase II. Subsequent to the quarter, FDA approval was received to begin U.S. human clinical trials for the Glaucoma Wick.
- Strategic Acquisitions: The company acquired a distributor of ophthalmic products in Europe during the quarter ended July 4, 1997.
- Risks: International operations expose the company to fluctuating exchange rates, foreign government regulations on fund transfers, and political instability. The company notes that foreign currency translation losses contributed to a decrease in "Other income (expense)" net.
- Future Guidance: Management expects to continue spending approximately 10% of revenues on R&D. The company anticipates continued profitability and believes future cash flow needs will be met by operations or additional financing if required.
Investor Verification Checklist
- Verify the sustainability of the 28.4% international sales growth and the impact of exchange rate fluctuations on future margins.
- Confirm the timeline and success probability of the FDA Phase II trials for the ICL and the U.S. trials for the Glaucoma Wick.
- Review the terms of the renegotiated $10 million line of credit and the specific financial covenants required to maintain it.
- Assess the impact of the 2.5% price decrease in the U.S. market on long-term revenue per unit.
- Monitor inventory levels, which increased to support new product rollouts, to ensure they do not become obsolete.